Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 6/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246177 | 1.00 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL23704504 | 1.00 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL27973851 | 0.91 | FOLH1 (0.49) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL31533361 | 0.87 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL1081373 | 0.87 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL31533362 | 0.87 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL1081372 | 0.87 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL6443925 | 0.84 | FOLH1 (0.55) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL6443921 | 0.84 | FOLH1 (0.55) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL20726 | 0.84 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082768-A1 | CONJUGATING REAGENTS AND CONJUGATES THEREOF | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| US-12078625-B2 | System and method for high-throughput radio thin layer chromatography analysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-03 | — | — | US | disclosed |
| US-20220244228-A1 | SYSTEM AND METHOD FOR HIGH-THROUGHPUT RADIO THIN LAYER CHROMATOGRAPHY ANALYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082768-A1 | CONJUGATING REAGENTS AND CONJUGATES THEREOF | PA2G4, CD47, IGLV6-57 | FOLH1 525/4885NAALAD2 302/4885ACE 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.